Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines?

Diabetes Research and Clinical Practice
Francisco Javier del Cañizo-Gómez, María Natividad Moreira-Andrés

Abstract

To assess the degree of control of modifiable cardiovascular risk factors (CRFs) in type 2 diabetic patients. Cross-sectional study in 501 patients with type 2 diabetes mellitus. The following parameters were used to define optimal control: glycated haemoglobin (HbA(1C)) <7.0%, fasting plasma glucose (FPG) <7.2 mmol/l, postprandial capillary glucose (PCG) <10.0 mmol/l, high-density lipoprotein cholesterol (HDL-C) >1.1 mmol/l, low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/l, triglyceride levels (TG) <1.7 mmol/l, systolic blood pressure (SBP) <130 mmHg, diastolic blood pressure (DBP) <80 mmHg, body mass index (BMI) <25 kg/m2, waist circumference (WC) <88 cm in women and <102 cm in men, and current non-smoking status. The use of various cardioprotective medications was also evaluated. Mean (+/-S.D.) age was 65.4 +/- 11.9 years, 218 (44%) were male. Ninety-six (19%) met coronary artery disease (CAD). Two hundred seven patients (41%) had an HbA(1C) <7.0%, 134 (27%) a FPG <7.2 mmol/l and 231 of 353 (65%) a PCG <10.0 mmol/l. Only 206 (41%) achieved an LDL-C <2.6 mmol/l, but 370 (74%) and 308 (62%) reached an HDL-C >1.1 mmol/l and a TG levels <1.7 mmol/l, respectively. In 359 (72%) patients DBP was <80 mmHg, but in only 136 (27...Continue Reading

References

Jul 1, 1976·The American Journal of Cardiology·W B KannelT Gordon
Oct 6, 1997·Endocrinology and Metabolism Clinics of North America·D E Goldstein, R R Little
Oct 7, 1997·Diabetes Care·M P Stern
Sep 2, 1998·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A Molarius, J C Seidell
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Feb 28, 2002·Archives of Internal Medicine·Wael K Al-DelaimyFrank B Hu
Mar 2, 2002·The American Journal of Geriatric Cardiology·Peter W F Wilson, William B Kannel
Oct 9, 2002·American Journal of Epidemiology·Sharon H SaydahFrederick L Brancati
Dec 28, 2002·Diabetes Care·UNKNOWN American Diabetes Association
Dec 28, 2002·Diabetes Care·John A Colwell, UNKNOWN American Diabetes Association
Jan 22, 2003·European Journal of Clinical Investigation·A M W SpijkermanC D A Stehouwer
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen

❮ Previous
Next ❯

Citations

Jun 7, 2005·Cardiovascular Diabetology·Christian BerneUNKNOWN URANUS study investigators
Jul 21, 2012·Diabetes & Metabolic Syndrome·Salwa Selim Ibrahim AbougalambouMohamed Azmi Hassali
May 27, 2008·Medicina clínica·Francisco Javier del Cañizo Gómez, María Natividad Moreira Andrés
Mar 24, 2009·Journal of the American Academy of Nurse Practitioners·Jeronimo JuradoJune Hart Romeo
Feb 16, 2007·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Matteo AnselminoUNKNOWN Euro Heart Survey Investigators
Apr 29, 2005·Diabetes/metabolism Research and Reviews
Mar 2, 2019·Circulation·Elisa VillalobosJoseph A Hill
Jul 23, 2013·Indian Journal of Endocrinology and Metabolism·Sheelu S SiddiqiAsad U Khan
Aug 13, 2011·The Biochemical Journal·Bogumil ZelentFranz M Matschinsky
Sep 10, 2008·Annals of Saudi Medicine·Fayzeh M MubarakKamel M Ajlouni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.